insights_auto
Why is ALKS down 2.60%?
Dive Deeperchevron_right
ALKS:NASDAQ
Alkermes Plc
$41.65
arrow_downward
-2.60%(-1.11) 1D
$41.65
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 6, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$42.64
High
$42.71
Low
$41.24
Mkt. cap
6.82B
Avg. vol.
2.08M
Volume
0.00
P/E ratio
108.22
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
Open
$42.64
High
$42.71
Low
$41.24
Mkt. cap
6.82B
Avg. vol.
2.08M
Volume
0.00
P/E ratio
108.22
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com